Bionetwork west 2010


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Bionetwork west 2010

  1. 1. Special Discounts Available! See pg. 7 for details Source Funding. Forge Partnerships. Manage Relationships. October 25-27, 2010 • The Ritz-Carlton, Laguna Niguel, CA Don’t Get Lost In The “Cattle Call” Of The Too-Big Industry Events. Spend Quality Time With The Right People At BioNetwork. • Gain insights from an unmatched speaker faculty and delegate base all eager to network and share knowledge • Maximize over 14 hours of networking activities built into the agenda so that you can have meaningful conversations over the course of three days • 1:1 partnering software makes it easy for you to schedule private meetings with our speakers and delegates before you get to the conference • Onsite facebook allows you to put a face to a name while at the conference. That way you can easily pinpoint who you want to speak with, instead of sifting through a sea of nametags Top Speakers You Will Meet At BioNetwork: Martin Reeves Ellen A. Lubman Robert Bagdorf Vice President, Business Strategic Transactions Group Vice President, Worldwide Development Bristol-Myers Squibb Business Development Cephalon Pfizer Inc. James Schaeffer Gregg Talbert Executive Director, Worldwide David Donabedian Managing Director, Mergers and Licensing and External Research Vice President, Strategic Acquisitions, Corporate Finance and Merck Alliances, US CEEDD Investment Banking (CFIB) Group GlaxoSmithKline Chris Seaton Eli Lilly Senior Vice President, Global Kimberly Rogers Robert Wills Transactions Vice President, Technology Vice President Alliance Management, Bayer Healthcare Assessment Pharmaceuticals Group Pharmaceuticals Allergan Johnson & Johnson PLUS - 2 Full Afternoons Of The Perfect Pitch – Biotech Investment Challenge! In this groundbreaking session, 4 Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts who will provide them with invaluable feedback to strengthen their pitches. Sponsors: Organized by: REGISTER Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 NOW! Email: Web:
  2. 2. New And Improved Networking Opportunities Improved One-To-One Private We make sure that you meet the people you came to see. Partnering Technology! Onsite Facebook Tired of sifting through a sea of name tags to find the person you want to meet? Upon check-in, the • Internal messaging capability BioNetwork team will be taking photos of all speakers and attendees so that you can easily spot the person • Scheduling blocking function you wish to network with. • Personalized meeting requests designed to avoid spam filters Onsite Message Board Placed in a central location by the registration area, the onsite message board allows you to leave notes for • Conference agenda accessible through partnering speakers or attendees that you are looking to connect with while at BioNetwork West. software Schedule Meetings Before You Arrive! You have the opportunity to reserve the One-To-One These pre-arranged rooms are available to be booked for 30 minute time blocks. 6 weeks out from Private Partnering Rooms for all three days of BioNetwork West 2010, you will receive a password allowing you to schedule One-To-One Private BioNetwork West where you can privately discuss the Partnering Rooms online. On our website you will find a list of registered attendees along with their contact specifics of your companies, your goals, and your details (viewable at their discretion), a brief description of their companies and partnership aspirations and a compounds. timetable of available meeting rooms. Upon receiving an accepted invitation from a potential partner, you *To view Who You Are Going To Meet At will be able to schedule a private partnering room. Please contact Sarah Cascone with any questions BioNetwork, please visit the website regarding the one-to-one partnering site at or 646-200-7497. Conference Day 1 Monday, October 25, 2010 7:45 Networking Breakfast For All Attendees 11:00 Case Study: BMS And Allergan Global Agreement For Conference Registration Sponsored By: Investigational Neuropathic Pain Medicine Tim Herpin 8:30 Chairperson’s Opening Remarks Director, Search and Evaluation, Strategy, Alliances and Transactions 8:45 Panel Session: Assessing The Deal-Making Landscape For 2010 - Bristol-Myers Squibb A Reflective Look At The Deals Done This Past Year Kimberly Rogers Martin Reeves Vice President Technology Assessment Vice President Business Development Allergan Cephalon This case study will look at the recent deal between BMS and Allergan for Jim Hattersley Allergan’s experimental therapy for neuropathic pain. This session will look into Vice President Corporate Business Development the strategic considerations behind the partnership from both BMS and Sun Pharmaceutical Industries, Inc. Allergan's perspectives and delve into the steps and timelines of the partnering Paul Darling process, the due diligence experience, and the status of the relationship today. Principal ZS Associates 11:40 Panel Session: Securing Funding In A Dry Market - The Industry John Hebert Has Changed, Have You? Associate Director, Corporate Development Mark Benedyk Genzyme Head Much has happened in the pharmaceutical space in the past year. Now is the The Pfizer Incubator LLC perfect time to get a read on how the industry fared in 2010. This opening Matthew Q. Reber panel session will analyze important developments in 2010 and its impact on Vice President the industry on a larger scale: Outlining major deals in 2010; evaluating Cowen Healthcare Royalty Partners financing in 2010; updates on the IPO window; Increase in foreign companies Matthew W. Kalnik, PhD buying into the US market and who’s partnering with whom? Senior Vice President, Strategic Planning and Business Operations Nabi Biopharmaceuticals 9:30 Panel Session: Industry Outlook - What Will The Pharma Space Look Like In 5 Years? Henry Skinner, PhD Managing Director Chris Seaton Novartis Venture Funds Senior Vice President, Global Transactions Bayer HealthCare Pharmaceuticals With limited opportunities in IPO and traditional forms of funding dried up, the market has had to employ creative methods of financing. This session will look Robert Bagdorf at the new financing models currently being used in the pharmaceutical Vice President, Worldwide Business Development industry: Corporate alliances, grants and government contracts; Monetizing Pfizer Inc. assets in your portfolio to raise capital; Assessing international licensing options; Executive Speaker and Panel Moderator Utilizing partnering as a means to gain capital. Campbell Alliance 12:25 Networking Lunch For All Conference Attendees In the wake of healthcare reform, the economic recession, industry consolidation and the patent cliff the pharmaceutical space has seen Sponsored by: considerable changes that will only continue. This session will look at the pharmaceutical industry outlook and provide predictions for what we can 1:35 Case Study Part 2: Merck/Schering Plough Merger expect in the coming years: impact of the healthcare reform on R&D and BD; effects of industry consolidation; how will big Pharma offset the negative James Schaeffer impact of dwindling pipelines. Executive Director, Worldwide Licensing and External Research Merck 10:15 Refreshment Break And Networking Opportunity Following up on the case study delivered at the BioNetwork East conference in March 2010, Dr. Jim Schaeffer joins us at BioNetwork West to continue the story of the merger of two giants in the industry – Merck and Schering Plough. Jim will share the process used during the integration and will share significant 2 Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: Web:
  3. 3. progress of the New Merck, the resulting pipeline, current partnership interests, The panelists will then have a chance to confer and choose “the perfect pitch” and finally, the next steps for the New Merck and your partner of choice. which will be presented at the awards ceremony cocktail reception immediately following the afternoon’s presentations. 2:15 IP/Regulatory Update – The Pathway For BioSimilars Panel of Experts Len Smith David Donabedian Principal Intellectual Property Counsel Vice President, Strategic Alliances, US CEEDD Medicis Pharmaceutical Corporation GlaxoSmithKline It is no surprise that the healthcare reform bill was passed this spring. What is Fred Aslan uncertain, however, is how pieces of this legislation will end up affecting the Vice President Pharma space. This session will look at how the new pathway works from the Venrock “biosimilars” vs. innovators perspective and how the availability of the pathway Kim Kamdar might relate to deal making in the future. Principal Domain Associates LLC 2:50 Refreshment Break And Networking Opportunity 3:30-3:50 Biotech #1 Presentation 3:30 The Perfect Pitch: Biotech Investment Challenge 3:50-4:10 Biotech #2 Presentation 4:10-4:30 Biotech #3 Presentation Presented by: 4:30-4:50 Biotech #4 Presentation Thomas Abbott 4:50-5:30 Feedback From Our Panel Of Experts President i3 Pharma Informatics *For more information on how you can participate in the Biotech Investment Challenge, please contact Mimi Fox at 416-597-4808 or email In this groundbreaking session, 4 Biotechs will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts. 5:30 Awards Ceremony And Cocktail Reception For All Attendees Here’s how it works: Presented by: Each Biotech will give a 20-minute company presentation. Then our panelists, VCs and Investment Banks will give their feedback on the strengths of the The “Perfect Pitch” Awards Ceremony and Cocktail Reception will be held directly pitches just heard, highlighting the portions of the presentations that piqued following this afternoon’s Biotech Investment Challenge. The award, presented their interest. This will give the presenting companies, as well as the audience, by i3 Pharma Informatics and our panel of expert judges, will be given to the best insight into what sparks the interest of potential partners and investors. This company pitch heard in the afternoon’s session. Join all conference attendees to session is a must attend for Pharma, Biotechs, and the investment community. hear who our panel of experts have chosen as the “Perfect Pitch” for 2010. Conference Day 2 Tuesday, October 26, 2010 7:45 Networking Breakfast For All Attendees Kris Ford Conference Registration Sponsored By: Vice President Business Development Intelliject 8:30 Chairperson’s Opening Remarks This case study will explore the recent deal between sanofi-aventis and Intelliject Jeff Totten from each side's perspective. This session will discuss the motivations behind the Vice President partnership and include the following: 1) Brief company overview, 2) Product Dean & Company overview, 3) Deal scope & terms, 4) Strategic considerations that led to the idea, 5) For s-a, why IJ & this deal; for IJ, why s-a & this deal, 6) The process, 7) Update 8:45 The Morning After - Ensuring Partnerships Work In The Harsh on the status of the relationship today, 8) Lessons learned. Reality Of Daylight Robert Wills 10:25 Refreshment Break And Networking Opportunity Vice President Alliance Management, Pharmaceuticals Group Johnson & Johnson 11:10 Hearing From The Little Guy - Spotlight On Small Biotechs Year after year, we hear from Big Pharma on what they look for in potential David Donabedian partners. But partnering is a two-way street. These panel sessions will bring Vice President, Strategic Alliances, US CEEDD together representatives from biotech companies and Big Pharma companies to GlaxoSmithKline offer their insight on the following: Laura Pierce Part 1- Defining The Difficulties Small Companies Face In Finding Vice President, Alliance Management A Partner In Big Pharma Bayer HealthCare Pharmaceuticals John Mendlein Alison Shurell Former CEO Vice President, Product Marketing Adnexus Therapeutics Intralinks Matthew Meyer Troy Windt Vice President Business Development Senior Director, Corporate Development Cerimon Upsher-Smith This panel session will highlight the problems small Biotechs face when trying to Maintaining relationships to work efficiently and effectively over time is traverse the big Pharma partnering market. Panelists will share their insights on paramount in a successful partnership. This session will examine the role of the following: 1) What is the follow up process like for inquiries with big Pharma the alliance management function in today’s partnering landscape. and how can it be improved?; 2) Outlining the process for finding the • Pinpointing specific examples of the benefits realized through effectively appropriate person withi your therapeutic area: How easy is the process? What managing your relationships could be changed? and 3) Highlighting other areas of this process that pose • Measuring the success of an alliance- outlining the metrics to gauge problems for small companies effectiveness • Providing the new team with a secure and neutral platform for information 11:50 Part 2- In A Competitive Bidding Process - What Do Small sharing and collaboration to ensure open communication throughout the Companies Look For In A Big Pharma Partner? life of the partnership Katrine Bosley CEO 9:45 Case Study: Sanofi-Aventis And Intelliject - North American Avila License For A Novel Epinephrine Auto-Injector Jason Rhodes Thomas Wiatrowski Executive Vice President and Chief Business Officer Director, U.S. Business Development Epizyme Corporation Sanofi-Aventis Sponsors: 3
  4. 4. It’s true that in most cases big Pharma has its pick of biotech companies. But Denise McGinn in a competitive bidding process, this is not the case. This session will bring Vice President of Licensing & New Business Development, together representatives from small Biotechs that have gone through a Pharmaceuticals Group, Johnson & Johnson competitive bid to better understand the following: This case study will discuss the co-promotion of Velcade in Japan from the • Identifying the due diligence process for a small company perspectives of both J&J and Takeda. From the strategic considerations that led to the • What attributes are important in a big Pharma partner? idea, to the developing evaluations and steps that led to the negotiations, to the due diligence experience, the deal signing and closing, and the status of the relationship 12:30 Networking Lunch For All Conference Attendees today. What was in it for Takeda? For J&J? What “lessons learned” were captured? Sponsored By: 3:00 Refreshment Break And Networking Opportunity 1:40 Part 3 - BIG PHARMA Perspective: Defining The Difficulties Small Companies Face In Finding A Partner In Big Pharma 3:30 The Perfect Pitch: Biotech Investment Challenge Ellen A. Lubman In this groundbreaking session, 4 Biotechs will be given the opportunity to present Strategic Transactions Group their “perfect pitch” to our audience of potential partners and investors as well as to Bristol-Myers Squibb our panel of experts. Yael Weiss Panel of Experts Director, Licensing & External Research - West Coast Gregg Talbert Merck Research Laboratories Managing Director, Mergers and Acquisitions, Corporate Jack Tupman Finance and Investment Banking (CFIB) Group, Eli Lilly Vice President, Corporate Business Development Frank Stokes Eli Lilly and Company Managing Director Understanding the challenges small biotechs face in gaining the partnership of R.W. Baird Big Pharma, it is important to also understand what Big Pharma expects and 3:30- 3:50 Biotech #1 Presentation needs from new partnerships. This panel provides important insights to 3:50- 4:10 Biotech #2 Presentation provide you with a Big Pharma perspective in building and sustaining 4:10- 4:30 Biotech #3 Presentation breakthrough partnerships. 4:30- 4:50 Biotech #4 Presentation 4:50- 5:30 Feedback from our panel of experts 2:20 Case Study: J&J / Takeda Co-Promotion For Velcade In Japan *For more information on how you can participate in the Biotech Investment Kyle D. Kuvalanka Challenge, please contact Mimi Fox at 416-597-4808 or email Vice President Millenium: The Takeda Oncology Company 5:30 Awards Ceremony And Cocktail Reception For All Attendees Conference Day 3 Wednesday, October 27, 2010 7:45 Networking Breakfast For All Attendees 10:00 Panel Session: Understanding The VC Due Diligence Process When Conference Registration Sponsored By: Deciding On Investing In A Company Howard D. Palefsky 8:30 Chairperson’s Opening Remarks Managing Director Montreux Equity Partners 9:00 Case Study: Compare And Contrast Two Co-Promotion Deals: Late Stage “Ready To Launch” vs. Early Stage Fred Aslan Vice President Jack Tupman Venrock Vice President, Corporate Business Development Eli Lilly and Company Kim Kamdar Principal Roger Graben Domain Associates LLC Senior Vice President, Operations & Business Development Kowa Pharmaceuticals America For small biotech companies, VC investment is critical to funding R&D projects in their pipeline. With the market for investment as it is, the VC capital is not as free Blake Salisbury flowing as it once was. Therefore, it is now more critical than ever to have a firm Director Corporate Business Development understanding of the due diligence process a VC conducts when evaluating a Eli Lilly and Company company. Michael A. Johnson Director Corporate Business Development 10:45 Refreshment Break And Networking Opportunity Eli Lilly and Company 11:30 Case Studies: Assessing The Impact Of The Emerging Markets On In December of 2009, Lilly concluded two co-promotion agreements – one with The Global Pharmaceutical Space Kowa Pharmaceuticals of America, for a new statin that had already been Daniel Bagi M.D. approved in the US but not yet launched, and another agreement with Incyte Managing Director Corporation, for an early stage new mechanism oral Rheumatoid Arthritis Riso Pharma Tech Inc. compound. This case study will include comments/discussion from the senior Part 1: Case Study BRIC (11:30-12:15) negotiators from the companies as they compare and contrast the differences in Part 2: Case Study: MENA (12:15-1:00) the two deal transaction processes highlighting some of the challenges/ opportunities and solutions associated with the different negotiations. It comes as no surprise that the emerging markets will play an integral role in the growth of the pharmaceutical industry. By conservative estimates, the E7 alone will be spending over 100B annually on pharmaceutical products by 2020. This section of the agenda will focus on trends in the emerging markets as well as highlight companies that have successfully capitalized on these growth markets. 1:00 Networking Lunch For All Attendees 2:00 End Of BioNetwork 2010 4 Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: Web:
  5. 5. About Our Sponsors Upsher-Smith is constantly looking for strong and trusted Campbell Alliance is the leading management partnerships through licensing, joint ventures, profit sharing, co- consulting firm specializing in the pharmaceutical and development and co-marketing arrangements. Upsher-Smith has a biotechnology industry. The firm's clients include most wide U.S. distribution network, experienced sales force and established customer of the world's top-20 pharmaceutical companies, as well as numerous emerging and relationships within all customer segments. Looking to the future, Upsher-Smith is midsize firms. Campbell Alliance is organized into practice areas, each specializing in a focused on: critical industry function: Brand Management, Business Development, Clinical • Building our current product pipeline Development, Managed Markets, Sales, and Trade and Distribution. From its locations • Co-promoting and acquiring women’s health products ready for commercialization in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, • Developing, in-licensing and acquiring CNS products focused primarily on treatments Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout for epilepsy & Parkinson’s disease. North America, Europe, and Japan. For more information on Campbell Alliance, please Our vision is to become a leader in providing therapies that empower people suffering visit from central nervous system (CNS) diseases to lead healthy, productive lives. Our focus is simple: Advancing pharmacotherapy. Improving life™. EvaluatePharma® is the premier source for commercial analysis in the pharma and biotech sector, delivering Dean & Company is a strategy consulting firm with a exclusive, trusted insight into industry performance. For unique mix of both traditional business strategy work and industry insiders and the investment sector, EvaluatePharma® supports value-enhancing a range of investing activities for large corporations, business decisions with unrivalled proprietary insight. technology start-ups, and equity funds. We work with senior executives to dramatically EvaluatePharma® sets new industry standards by providing consensus forecasts on improve and sustain their company's performance. Dean & Company has an global drug sales. Our expertise and innovative approach has driven other pioneering established, highly successful track record in generating actionable and quantifiable developments including Merge Company tool, Calendar of Events and interactive NPV results for our clients in the Life Sciences. These include a number of the largest global Analyzer. companies as well as emerging leaders in the Pharmaceuticals, Biotechnology, and But it's not just our expertise that sets us apart. The reliability of our data and depth of Medical Devices & Technology industries. We additionally have developed specialized coverage provide clients with commercial insights simply not available anywhere else. expertise in the Vaccines industry. The hallmark of our work in life sciences, as in other industries, is our ability to deliver highly quantitative, analytic-driven solutions to Gerson Lehrman Group (GLG) manages the world’s leading expert complex business problems and the development of practical, action-oriented network and provides software and services to support a marketplace for recommendations and their associated measurable impact on the bottom-line. Our life expertise. GLG's unparalleled network of leading expert consultants, sciences capabilities extend across the following industry challenges and issues: known as the GLG CouncilsSM, includes more than 175,000 subject Licensing/Strategic Alliances/M&A Due Diligence, Portfolio/Life Cycle Management, matter experts and many key opinion leaders (KOLs) who educate and provide insight Product Commercialization & Launch, Manufacturing & Distribution Strategy, to decision makers worldwide. Healthcare companies use GLG to accelerate business Competitive Intelligence/Benchmarking, Marketing Strategy, Pricing & Reimbursement, development research and gather superior market intelligence. GLG’s expertise reaches R&D Productivity. every sector of the healthcare industry, from the mid-sized and most specialized organizations to some of the largest pharmaceutical, biotechnology, healthcare services, IntraLinks® provides enterprise-class solutions which facilitate and medical device and supply companies in the world. Visit us at the secure, compliant and auditable exchange of critical information, collaboration and workflow management inside i3 is a full-service, global contract research company providing and outside the enterprise. Our on-demand solutions help you organize, manage, share clinical research services for biotech and pharmaceutical clients. i3 and track information, enabling you to accelerate your workflow, optimize your takes a 360-degree view of health care to help its global business processes and realize new profit potential. Since 1997, IntraLinks has been pharmaceutical, biotechnology, and medical device clients bring safe and effective used on critical business processes by more than 750,000 users from 90,000 products to market quickly and help demonstrate their value, leading to increased ROI organizations worldwide, including 10 of the top 10 pharmaceutical companies and and better patient care. hundreds of biotechs. IntraLinks counts 800 of the Fortune 1000 as clients, including i3’s Pharma Informatics combines unparalleled data assets, online tools, and scientific enterprises such as AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank expertise to help you attain a clearer understanding of your products’ potential and and the FDIC. For more information, visit corresponding market dynamics—so you can make more rapid, informed decisions throughout development and commercialization. Over 25 years, ZS Associates has helped clients in more than 70 countries measurably improve their results through our comprehensive expertise in Founded in 1876, Eli Lilly and Company is now the 10th largest sales and marketing consulting, capability building and outsourcing. Our pharmaceutical company in the world. Lilly has steadfastly remained clients include multinational, midsize and entrepreneurial companies around independent, but not isolated. Across the globe, Lilly has developed the world, with a deep and long-standing emphasis on the healthcare sector, and the productive alliances and partnerships that advance our capacity to develop innovative pharma/biotech sector in particular. Through our business development and licensing medicines at lower costs. Lilly is consistently ranked as one of the best companies in the practice area, we support both large and small pharma/biotech companies with services world to work for, and generations of Lilly employees have sustained a culture that ranging from strategic portfolio evaluation and business development strategy to values excellence, integrity, and respect for people. Lilly's global employees number evaluation of specific potential partners and deals. ZS has more than 1,300 approximately 40,000, and our medicines are marketed in 143 countries. Lilly has major professionals serving clients from 19 offices worldwide. research and development facilities in eight countries and conducts clinical trials in more than 50 countries. Lilly makes medicines that help people live longer, healthier, Sanofi-Aventis, a leading global pharmaceutical company, more active lives. discovers, develops, and distributes therapeutic solutions to address the world’s expanding healthcare needs. We work to Symphogen is developing superior antibody therapeutics to help prevent and treat the diseases that we know of today, as well as those we may face people with seri¬ous diseases. With its proprietary Symplex™ tomorrow. With approximately 100,000 dedicated professionals in more than 100 discovery and Sympress™ manufacturing platforms, the countries, sanofi-aventis is devoted to advancing healthcare around the world. We are company captures the diversity and specificity of the natural committed to maintaining the innovative approach to pharmaceuticals established by immune response in rationally designed recombinant antibody composi¬tions. our parent company, headquartered in Paris, France. Our U.S. affiliate, with Symphogen is maturing a diversified pipeline of internal and partnered prod¬ucts headquarters in Bridgewater, New Jersey, employs approximately 15,000 professionals across multiple indications including cancer and infectious disease. Its technologies and located throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare expertise within the antibody field have been validated through corporate partnerships organization working to meet the needs of physicians and their patients. At sanofi- with pharmaceutical companies in the US, Europe, and Japan. Symphogen’s corporate aventis, each and every day we work for what really matters: health .For more office is located in Lyngby, Denmark and employs 70 people. Symphogen’s US information, visit subsidiary, Symphogen, Inc. is headquartered in Princeton, NJ. SPONSORSHIP OPPORTUNITIES AVAILABLE Don’t miss your chance to be in front of the top pharmaceutical and biotech companies in North America. If you are offering a solution, service, or technology that will help companies improve research and development, search and evaluation, licensing, strategic alliances, due diligence, or simply want to show how you are the partner of choice in fueling opportunities for increasing drug pipelines, contact Jodi Richter, Director of Sponsorship and Sales, 646-200-7485 or email Sponsors: 5
  6. 6. About Our Media Partners BioPharm Insight provides the most comprehensive Laboratory Network is the premier Internet source of useful information and forward-looking insight to help you easily and timely information about the laboratory industry. The site find the answers you need within the Biotechnology and Pharmaceutical industry. is directed to chemists, researchers, laboratory managers and research directors, It includes the entire drug discovery and development pipeline, approved drugs, as well as users, purchasers and manufacturers of laboratory equipment, licensing deals, pharmaceutical sales/projections, management contacts and chemicals, and supplies. Laboratory Network provides daily news updates and more. reports on business and technology trends vital to the industry. BioPharm International integrates the science and business of Established in 1965, the Licensing Executives Society (U.S.A. and biopharmaceutical research, development, and manufacturing. Canada), Inc. (LES) is a professional society comprised of over 6,000 We provide practical, peer-reviewed technical solutions to enable members engaged in the transfer, use, development, manufacture biopharmaceutical professionals to perform effectively. BioPharm is the longest- and marketing of intellectual property. The LES membership includes a wide running peer-reviewed publication serving an international audited audience range of professionals, including business executives, lawyers, licensing involved in the development, manufacturing of therapeutics and management of consultants, engineers, academicians, scientists and government officials. Many related business issues. large corporations, professional firms, and universities comprise the Society's membership. Licensing Executives Society (U.S.A. and Canada), Inc. is a member Bioresearch Online is the premier sourcing site for industry society of the Licensing Executives Society International, Inc. (LESI), with a professionals. Use our supplier directory, product showcase, and worldwide membership of over 12,000 members in 30 national societies, offline search service to expedite your discovery of new products and services. representing over 80 countries. Our goal is to help buyers, like you, identify and select the right suppliers. Life Science Leader strives to be an essential business tool for BioWorld Today, the newspaper of record for the biotechnology Life Science executives. The editorial is designed to provide industry, is read by thousands of biotechnology professionals readers with content pertaining to the life cycle of Life Science worldwide for its hard-hitting, objective news reporting and insightful analysis products and services. Our goal is to provide information that helps high-level covering news on public companies and hard-to-find information on private industry personnel improve profits and overcome hurdles within the industry. companies. Delivered by e-mail every business morning, we are also found exclusively online at For more than 25 years, Med Ad News has provided the busy pharmaceutical executive with need-to-know business CanBiotech - A Portal and B2B Outsourcing Marketplace for the information. Each issue delivers broad coverage and penetrating analysis of Biotech and Pharmaceutical Industry. The Marketplace features the issues, events, trends, and strategies shaping the pharmaceutical industry. Outsourcing Services Showcase; the Portal features our Published monthly, Med Ad News provides exclusive content examining historical biopharmaceutical and venture capital directories and databases. Publications trends pertaining to and current events affecting the sales and marketing of include the Bio Outsourcing Asia© Publication. medicines and the companies that manufacture them. To learn more about Med Ad News and other products from Canon IMM Inc. visit or CurrentPartnering is an online provider of best practice, call 215-944-9800. business information and intelligence for dealmakers. The core of our service is to provide access to latest best practice, business Published by Espicom Business Intelligence, Pharma Agreement intelligence and information for dealmakers. We search out the latest information News is the twice-monthly business publication that concisely so you don’t have to and place it in one location, saving you precious time and reports on hundreds of agreements and deals between phamaceutical companies resources. CurrentPartnering is a publisher in its own right, publishing a series of worldwide. For further information and to order your subscription today, visit reports each year and providing access to critical decision making and best practice intelligence from leaders in the partnering field. Our most recent report titles include: Pharmaceutical Online is the online industry standard for • Option & Evaluation Agreements in Pharma & Biotech pharmaceutical manufacturing. Use our supplier directory, • Royalty Financing Terms and Agreements in Pharma, Biotech & Diagnostics, 2nd product showcase, and offline search service to expedite your discovery of new Edition products and services. Our goal is to help buyers, like you, identify and select • Practical Guide to Finding Partners in Pharma & Biotech, 3rd Edition suppliers. • Clinical Stage Partnering Terms and Agreements in Pharma & Biotech, 2nd Edition Pharma Connections Worldwide® is the leading professional For more information about us, please visit business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is Cutting Edge Information delivers an innovative approach to to provide a conduit for delivery of premiere content coupled with the right comprehensive pharmaceutical and biotechnology benchmarking clientele in order to facilitate business development opportunities amongindustry data. CEI offers objective, proprietary primary and secondary research professionals responsible for making key decisions in a global marketplace. on critical industry issues. CEI offers customized consulting services and a growing library of targeted and insightful pharmaceutical research reports. PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting Drug Discovery Online covers drug discovery like no other the life-sciences industry, covering a range of issues from molecule through Internet site. Each day we present the most interesting, useful market. PharmaVOICE's more than 17,500 U.S.-based subscribers are also kept feature stories, case studies, industry news, and newswire feeds related to the abreast of the latest trends through additional media resources, including science and business of discovering new drugs. Throughout the year Drug WebSeminars, Podcasts, Videocasts, and White Papers. Discovery Online presents news and opinions on the latest discovery technology, from organic synthesis and the manual isolation of new compounds from exotic The Scientist, the award-winning magazine of the life sciences, plants, to combinatorial chemistry and high-throughput screening. provides compelling print and online coverage of the latest developments in the life sciences including research, FierceBiotech is the biotech industry's daily monitor. Senior technology, and business. We entertain and inform our readers, keeping them biotech industry professionals rely on FierceBiotech to stay up to up-to-date with latest news, events, culture, innovations and career advice. Visit speed on biotech corporations, FDA approvals & regulations, industry mergers & us at acquisitions, clinical trials, and more through our comprehensive website and free email newsletter. Updated daily on the web or twice-monthly in print, World Generic Markets distils the important generic market news Georgia Bio ( is the private, non-profit association worldwide. Published by Espicom Business Intelligence, World representing more than 300 pharmaceutical, biotechnology, Generic Markets is fast becoming the publication of choice for drug developers, medical device and diagnostic companies, healthcare systems, universities, the pharmaceutical manufacturers, service companies, commerce, investors and research institutes and other organizations involved in the research and regulators - make sure you get the benefits too! For further information and to development of life sciences products that improve the health and well-being of order your subscription today, visit people, animals and the environment worldwide. 6 Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 Email: Web:
  7. 7. Registration Information The Perfect Pitch: Biotech Investment Challenge Sponsorship Opportunities Available Find out how you can sponsor BioNetwork 2010. Unlike huge industry In these innovative sessions eight Biotechs will be given the opportunity to events, BioNetwork allows you to meet senior executives from different present their “perfect pitch” to our audience of potential partners and Pharmaceutical and Biotech companies on a one-to-one basis. For investors as well as to our panel of experts. sponsorship inquiries please contact: Jodi Richter, Director of Sponsorship and Sales, 646-200-7485 or email Each Biotech will give a 20 minute company presentation highlighting their current projects. Then our panelists, consisting of big Pharma, VCs and Investment Banks will give their feedback on the strengths of the pitches just heard- highlighting the portions of the presentations that piqued their interest. Tell Us Who You Want To Meet At This will not only give the presenting companies the platform to attract new partners, but will also give the presenting companies, and audience alike, BioNetwork 2010! insight into what sparks the interest of potential partners and investors. This If you're already registered or are planning to register for BioNetwork session is a must attend for Pharma, Biotechs, and the investment community. 2010, tell us about five people you would like to meet at the event. We will reach out to them on your behalf to get them registered. Once they The panelists will then have a chance to confer and choose “the perfect pitch” register, we will notify you, so you can set up one-on-one meetings with them onsite at BioNetwork. which will be presented at the awards ceremony cocktail reception immediately following the afternoon’s presentations. Send your list of names, including job title, company, phone and email address to or go to our website at If your company is interested in joining one of the Investment and complete the online form. Challenge afternoons, contact Mimi Fox at 416-597-4808 or email! Spaces are limited so sign up today! Hotel Information Ritz Carlton Laguna Niguel One Ritz Carlton Drive, Dana Point, CA 92629 Conference Pricing Tel. 949-240-2000 Fax. 949-240-0829 Pricing Register & Pay Register & Pay Register & Pay By 7/30/2010 To By 8/31/2010 To By 9/30/2010 To Experience genuine renewal at The Ritz-Carlton, Laguna Niguel. Situated Get $600 Off Get $400 Off Get $200 Off Full Price atop a 150-foot bluff, this peaceful sanctuary soars above the standard Laguna hotels with refined elegance, a graceful atmosphere and impeccable service. Located halfway between Los Angeles and San Diego, the luxury 3 Day Conference $2,600 $2,800 $3,000 $3,200 oceanfront resort offers panoramic white-water views of the Pacific. The Ritz-Carlton, Laguna Niguel is a luxury resort like no other. Group Discounts Register & Pay Register & Pay Register & Pay BioNetwork has procured a special conference rate of $330.00 per for Teams of 2 night (plus tax). To book your reservations, call the Ritz Carlton Laguna By 7/30/2010 To By 8/31/2010 To By 9/30/2010 To or More Niguel at 949-240-2000 or 1-800-241-3333 and identify yourself as a Get $800 Off Get $600 Off Get $400 Off Get $200 Off BioNetwork attendee. Rooms are limited and are on a first come, first served basis, so make your reservations as soon as possible. The discounted 3 Day Conference $2,400 $2,600 $2,800 $3,000 rate expires September 24th, 2010. After September 24th, rooms may still be available, so inquire with the hotel if you have missed the cut off date. PURCHASE SELECT AUDIO PRESENTATIONS* FROM THIS EVENT! Airport Options Can't make it to BioNetwork 2010 or worried that there is too much information to digest in a • John Wayne/Orange County Airport; SNA (25 minutes/23 miles) few short days at the event? No need to worry. You can purchase select audio presentations to share with your entire team. • Long Beach Airport; LGB (45 minutes/44 miles) Register for the event today and for an additional $250 gain access to select audio • Los Angeles International Airport; LAX (60 minutes/63 miles) presentations from this event. Can’t attend? Purchase the CD-ROM only for $580 *Presentations available are at the approval of conference speakers. Allow 3-4 weeks after event • San Diego Lindbergh Field Airport; SAN (75 minutes/67 miles) date for shipping. Small Biotechs & University Pricing Available! For every registration received for Bio Network, WBR will donate a portion of the registration fee to Please inquire about discounted rates at or contact Smile Train. For more information about WBR’s Mimi Fox at, 416-597-4808 to learn more. involvement with Smile Train, please visit Please Note: Delegate Substitutions And Cancellations: • To secure your team discount, register online at or contact Bill Penney at • You may substitute delegates at any time by providing reasonable advance 1-866-691-7771 or notice to WBR. • Team discounts must be booked and paid for at the same time. Team discounts do not apply to • For any cancellations received in writing not less than thirty (30) days prior to sponsoring or exhibiting companies or non pharmaceutical, biotech company. the conference, you will receive a 75% credit to be used at another WBR • All discounts are taken off the full conference price. No two discounts or offers can be combined. conference which must occur within one year from the date of issuance of • Payment is due in full at the time of registration. Your registration will not be confirmed until such credit. An administration fee of 25% of the contract fee will be retained payment is received and may be subject to cancellation by WBR for all permitted cancellations. • For payment methods and to register now, please visit • There are no refunds given under any circumstances. Sponsors: 7
  8. 8. 10386.005/GS Special Attention Mailroom: If undeliverable to addressee, this time Discounts Available! See pg. 7 for details sensitive information should be forwarded to the Source Funding. Forge Partnerships. Manage Relationships. VP of Business Development October 25-27, 2010 • The Ritz-Carlton, Laguna Niguel, CA • “I have always found the BioNetwork meetings very productive. Due to its more 535 Fifth Avenue, 8th Floor intimate setting, it is very easy to meet with companies and share ideas. This setting coupled with a well organized and professionally managed conference always New York, NY 10017 delivers a positive experience.” - Mark Dennish, Vice President, Business Development, Daiichi Sankyo WBR Don’t Miss These Exclusive Networking Opportunities “BioNetwork is a top tier biotech/pharma industry executives with many strong partnering functions Unique To BioNetwork: conference, integrating business development October 25-27, 2010 Development, Sun Pharmaceutical Industries, Inc. Laguna Niguel, CA - Jim Hattersly, Vice President, Corporate Business The Ritz-Carlton, - great venues & very productive results” • 30+ private one-to-one meeting • 5 networking refreshment breaks opportunities • 3 networking breakfasts When registering please provide the code above. • 23 interactive and educational panel • 3 networking lunches sessions and case studies presented by executive level industry leaders • 2 rewarding cocktail receptions Your priority booking code is: • Biotech Research Presentations at • 1 essential opportunity to source the Perfect Pitch: Biotech funding, forge partnerships, and Investment Challenge manage relationships with the decision makers in your industry Sponsors: Organized by: REGISTER Call: 1-888-482-6012 or 1-646-200-7530 Fax: 1-646-200-7535 NOW! Email: Web:
  9. 9. Organized by: Can’t make it to: or afraid there is too much information to digest in just a few days? Get Access to hours of valuable This Session Content is available for a sessions and take-ways anytime, fraction of the registration price. anywhere... You can view and listen to the content when Now you can view this outstanding conference you want, where you want and as many times content on your PC or laptop with a CD-ROM that as you want. puts you front and center at these informative sessions. You'll hear our expert speakers as they And if you attend BioNetwork 2010, this take you through the PowerPoint slides that Conference CD-ROM set is only $250! illustrated their talks. (That’s a $580 value!) This user friendly format allows you to: • Gain valuable insight from your peers and competitors in various Fortune 500 Industries VIP Package: $250 without leaving the office. (Select any package to attend the event • Share with your colleagues at work. and for an additional $250 get the • Stay up to date with the latest strategies, tactics conference CD ROM*) and trends in your industry. CD ROM ONLY: $580 * Now you can share what you learnt at BioNetwork 2010, with your colleagues. *Presentations available are at the approval of conference Don’t leave them in the dark. Purchase the speakers. Not all presentations will be published. Allow 3-4 weeks after event date for shipping. CD ROM today!